4DMedical (4DX) investor relations material

Market Opportunity and Product Differentiation

• Targeting the $1.15 billion U.S. VQ scan market and a global opportunity of $2.6 billion, with over one million annual scans in the U.S.

• CT VQ is the only technology enabling visualization of lung blood flow without injected contrast or radiotracers, offering significant workflow and patient benefits.

• The solution leverages existing CT infrastructure and protocols, reducing procedure time and complexity compared to nuclear medicine alternatives.

• Broad accessibility leverages 14,500 CT scanners in the U.S., extending advanced imaging to rural and community facilities.

• The technology is supported by over 100 patents, nine FDA clearances, and hundreds of peer-reviewed publications.

Commercial Progress and Strategic Partnerships

• Philips will distribute CT VQ across North America with a minimum order commitment of US$10 million over two years and dedicated sales and clinical teams.

• The Philips partnership includes exclusivity for U.S. government sales and leverages Philips' large PACS install base.

• Joint marketing and co-branding initiatives with Philips, including the RSNA 2025 launch, are generating significant interest among leading U.S. radiologists and pulmonologists.

• The agreement provides revenue visibility through milestone-based financial commitments.

• The company is well funded, with cash in the bank and expectations of further capital from exercised options.

Competitive Advantages and Defensibility

• Maintains a strong competitive moat through a robust patent portfolio, first-mover advantage, and deep R&D expertise.

• The technology is not solely reliant on AI, reducing regulatory risk as AI-based imaging faces increasing FDA scrutiny.

• Reference customers at top U.S. academic medical centers are a strategic focus to drive broader market adoption.

• Ability to process archived CT scans for retrospective analysis and reimbursement adds further value.